AVTX
Avalo TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
AVTX vs peer average
66/100
AVTX vs. peer average (C vs. D)
Grade spread
B 1 · C 2 · D 3 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
MLTX is the first available peer comparator.
Direct HS clinical-development comparator: MoonLake is studying sonelokimab in Phase 3. Its different mechanism, later stage, and broader program make it unsuitable as a simple valuation multiple. [MoonLake release](https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-announces-week-52-results-sonelokimab-its-phase-3-vela)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
AVTX
Avalo Therapeutics
MLTX
MoonLake Immunotherapeutics
Grade
C
F
Momentum
2
8
Value
58
41
Sentiment
60
-
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs MLTX
AVTX / MLTX
Grade Position
In line
AVTX vs. peer average (C vs. D)
66/100
Momentum
2
MLTXValue
58
AVTXSentiment
60
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs AVTX
MLTX is the first peer returned for this comparison set.